Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Orchid Pharma Limited (ORCHPHARMA.NS)
Narsinghpur, IN
Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products. Its comprehensive API portfolio encompasses oral and injectable cephalosporins, various veterinary pharmaceuticals, and non-antibiotic substances. The company maintains a multi-faceted therapeutic footprint, with offerings in areas such as anti-infectives, anti-inflammatory agents, central nervous system disorders, cardiovascular health, and nutraceuticals, alongside other oral and sterile formulations. Furthermore, it provides sophisticated new drug discovery (NDD) and pharmaceutical research and development (R&D) services. Orchid Pharma also engages in global trade, distributing its products to roughly 40 nations worldwide. Additionally, it offers comprehensive liaison and support services to its clientele, covering areas like regulatory compliance, pharmacovigilance, product testing and release, sample retention, coordination with service providers, and business expansion initiatives. The entity, originally incorporated as Orchid Chemicals & Pharmaceuticals Limited, adopted its current name, Orchid Pharma Limited, in October 2015. Established in 1992, its corporate headquarters are situated in Chennai, India. The company operates as a subsidiary of Dhanuka Laboratories Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.26% | +0.95% | +27.79% | +15.43% | -16.93% | -4.56% | -2.28% | +73.00% | -50.67% | +3,924.17% | +3,924.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-12.0% Q1'26: +0.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-79.4% Q1'26: +6.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.5% Q1'26: -62.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.7% Q1'26: +7.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.5% Q1'26: +5.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.14× ★ Q1'26: 0.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 3 Rev. Ana. 2 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
11.64B
est: 24.81B (-53.1%)
|
6.66B
est: 24.81B (-73.2%)
|
8.19B
est: 8.81B (-7.0%)
|
9.22B
est: 9.29B (-0.7%)
|
8.04B
7.53B – 8.31B
-13.5% YoY
|
15.13B
14.18B – 15.64B
+88.2% YoY
|
20.19B
18.93B – 20.87B
+33.4% YoY
|
| EBITDA |
3.53B
est: 3.97B (-11.1%)
|
1.43B
est: 3.97B (-64.0%)
|
1.42B
est: 1.75B (-19.0%)
|
1.45B
est: 1.85B (-21.7%)
|
1.60B
1.50B – 1.65B
-13.5% YoY
|
3.01B
2.82B – 3.11B
+88.2% YoY
|
4.01B
3.76B – 4.15B
+33.4% YoY
|
| EBIT |
1.37B
est: 1.20B (+13.7%)
|
874.73M
est: 1.20B (-27.3%)
|
1.08B
est: 3.14B (-65.5%)
|
1.10B
est: 3.31B (-66.7%)
|
2.86B
2.68B – 2.96B
-13.5% YoY
|
5.39B
5.05B – 5.57B
+88.2% YoY
|
7.19B
6.74B – 7.43B
+33.4% YoY
|
| Net Income |
-1.31B
est: 38.24M (-3,528.4%)
|
463.18M
est: 38.24M (+1,111.3%)
|
921.67M
est: 1.12B (-17.8%)
|
996.57M
est: 944.12M (+5.6%)
|
114.49M
107.19M – 121.79M
-87.9% YoY
|
912.89M
688.22M – 1.14B
+697.4% YoY
|
1.99B
1.86B – 2.12B
+118.1% YoY
|
| SGA |
1.40B
est: 1.41B (-0.8%)
|
231.23M
est: 1.41B (-83.6%)
|
322.83M
est: 499.66M (-35.4%)
|
882.37M
est: 526.86M (+67.5%)
|
455.84M
427.41M – 471.30M
-13.5% YoY
|
858.08M
804.55M – 887.19M
+88.2% YoY
|
1.14B
1.07B – 1.18B
+33.4% YoY
|
| EPS |
-16.84
est: 0.75 (-2,333.4%)
|
11.35
est: 0.75 (+1,405.3%)
|
19.06
est: 23.20 (-17.8%)
|
19.65
est: 18.97 (+3.6%)
|
2.30
2.11 – 2.40
-87.9% YoY
|
18.00
13.57 – 22.43
+682.6% YoY
|
40.00
36.76 – 41.76
+122.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mridul Dhanuka | Whole Time Director | 39M | male |
| Manish Dhanuka | MD & Director | 39M | male |
| Kapil Dayya | Company Secretary & Compliance Officer | — | male |
| Prabhu Vinayagam | Head of Medico Marke | — | male |
| Praga Kumar Patro | Head of Information Technology | — | male |
| S. Srinivasan | Head of CTD & IPM | — | — |
| Sivaswami Mani | President of API, CSR and SH & E | — | male |
| A. Chandrasekar | Vice President of Operations | — | — |
| Sunil Kumar Gupta | Chief Financial Officer | — | male |
| Ashok Clifford | Head of Human Resources | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORCHPHARMA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
